HELLS and cancer: The results show that HELLS expresses significantly differently in nine of 12 cancers for immune subtypes, including ACC (six subtypes), KIRP (six subtypes), LGG (four subtypes), LIHC (five subtypes), LUAD (five subtypes), LUSC (five subtypes), PAAD (five subtypes), PRAD (four subtypes), and SARC (five subtypes) (Figures 6A–I).